ELAN

In the past six months, Elanco's stock has fallen by -0.99% weekly and -4.10% monthly, but increased by 18.61% over the last year. Key events include the Q1 2026 earnings call on May 6, 2026, and strong Q2 2026 results where Elanco reported adjusted earnings of $0.34 per share on $1.37 billion revenue, exceeding expectations. Fitch Ratings upgraded Elanco's Long-Term Issuer Default Rating to 'BB+' due to a strengthened competitive position and $650 million in debt reduction since 2024. In August 2026, the company completed a 25,000-square-foot expansion at its Elwood, Kansas biologics facility to increase monoclonal antibody manufacturing capacity. At the Morgan Stanley Global Healthcare Conference on September 15, 2026, management highlighted strong demand for pet health products, particularly parasiticides and dermatology, driven by an extended 'tick and itch season.' Stifel reiterated a 'Buy' rating and a $33.00 price target on September 18, 2026, based on strong adoption expectations for the Befrena product. Elanco is scheduled to report its Q3 2026 results on November 6, 2026.